Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis

Abstract

US Food and Drug Administration.

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response

“…A previous report of the NeoAdjuvant Lapatinib and/or Trastuzumab Treatment Optimisation (NeoALTTO) phase III, randomized trial showed that dual anti-HER2 blockade with lapatinib and trastuzumab combined with weekly paclitaxel significantly increased the rate of pathological complete response (pCR) compared to trastuzumab and weekly paclitaxel (51·3% vs. 29·5% respectively; p= 0·0001) (7). In a recent meta-analysis funded by the US Food and Drug Administration (FDA) involving 11·955 patients, reaching pCR after neoadjuvant therapy was significantly associated with better event-free survival (EFS) and overall survival (OS), particularly in the HER2-positive population (N= 1·989) irrespective of hormone receptor status (Hazard Ratio (HR) 0·39 for EFS and HR 0·34 for OS) (8).…”

Predictive and Prognostic Role of Tumor-Infiltrating Lymphocytes for Early Breast Cancer According to Disease Subtypes: Sensitivity Analysis of Randomized Trials in Adjuvant and Neoadjuvant Setting

“…It is well known that the achievement of pCR represents the main prerequisite to improve both disease-free survival and overall survival (OS) [20]. Several studies have shown that higher TIL infiltration in the pretreatment core biopsy specimen is a predictor of response to neoadjuvant chemotherapy [21][22][23].…”

Usefulness of miRNA profiles for predicting pathological responses to neoadjuvant chemotherapy in patients with human epidermal growth factor receptor 2-positive breast cancer

“…However, several previous studies of miRNA expression profiles of neoadjuvant chemotherapy for patients with HER2-positive breast cancer did not classify patients according to hormone receptor status (34,35). The pathological response and survival benefit of neoadjuvant chemotherapy with trastuzumab reportedly differs between two HER2-positive subtypes divided by hormone receptor status (10). Therefore, we classified HER2-positive breast cancer into subtypes based on ER status and subsequently analyzed miRNA expression.…”

“…However, there exists a discrepancy in the pathological responses and survival benefits of neoadjuvant chemotherapy between these two HER2-positive subtypes (10). Therefore, Usefulness of miRNA profiles for predicting pathological responses to neoadjuvant chemotherapy in patients with human epidermal growth factor receptor 2-positive breast cancer new predictive markers in combination with conventional markers, including immunohistochemical ER and HER2 status, are required.…”